What is prostate cancer?
Prostate cancer develops when abnormal cells in the prostate gland in an uncontrolled way, forming a malignant tumour.
Prostate cancer is the second most common cancer diagnosed in men in Australia and the third most common cause of cancer death. One in 6 men will be diagnosed with prostate cancer by the age of 85. It is more common in older men, with over 63% of cases diagnosed in men over 65 years of age.
In 2016, 19,305 new cases of prostate cancer were diagnosed in Australia.
Early (localised) prostate cancer refers to cancer cells that have grown but do not appear to have spread beyond the prostate.
There are two stages of advanced prostate cancer:
- locally advanced prostate cancer where the cancer has spread outside the prostate to nearby parts of the body or glands close to the prostate
- metastatic prostate cancer where the cancer has spread to distant parts of the body.
In 2018, there were 3264 deaths caused by prostate cancer.
The five year survival rate for prostate cancer is 95%.
Prostate cancer symptoms
Early prostate cancer usually does not cause symptoms.
Advanced prostate cancer symptoms can include:
pain while urinating
blood in the urine or semen
a weak stream
pain in the back or pelvis
weak legs or feet.
More widespread disease often spreads to the bones and causes pain or unexplained weight loss and fatigue.
Causes of prostate cancer
Some factors that can increase your risk of prostate cancer include:
age, increasing rapidly after 50 years of age
a father or brother diagnosed with prostate cancer before the age of 60.
There is an association with high testosterone levels.
Diagnosis of prostate cancer
If your doctor suspects you may have prostate cancer, you may have one or more of the following tests:
PSA blood test
A prostate specific antigen (PSA) blood test measures the PSA levels, the proteins made by both normal and cancerous prostate cells. Because PSA levels can be variable, it is common for your doctor to use results from more than one blood test, over time, to help determine your risk of prostate cancer.
Some men with prostate cancer have normal PSA levels, and only one in three men with an elevated PSA level has cancer. As it is not a definitive test, a PSA test is normally used with other tests to diagnose prostate cancer.
There is a lot of confusion around PSA testing. Click here for more information.
Digital rectal examination
Digital Rectal Examination (DRE) is no longer recommended as a routine test for men who do not have symptoms of prostate cancer. As not all prostate cancers produce high levels of PSA, it may still be used to check the prostate before doing a biopsy.
A biopsy removes small pieces of tissue from different parts of the prostate with the aid of a rectal ultrasound, for examination under microscope. It is used to detect the disease and determine its aggressiveness (the Gleason score of 1-5 is added from two samples to form a score out of 10; low scores of 6 or less, indicate slow growing disease).
If cancer is detected in your prostate, you may have other tests such as MRI, CT or bone scans to see if the disease is contained to the prostate or to help with management and treatment options.
Treatment for prostate cancer
Treatment depends on the extent of the cancer.
The staging system used for prostate cancer is the TNM system, which describes the stage of the cancer from stage 1 to stage 4 . Ninety per cent of patients present with local disease. Bone and CT scans are used to determine spread.
Active surveillance monitors prostate cancer that is not causing symptoms and is considered low risk (ie cancer is small and slow growing and unlikely to spread). Generally active surveillance involves PSA tests every 3-6 months, rectal examination every 6 months and MRI scans and biopsies at 12 months and 3 years.
Watchful waiting is another form of monitoring prostate cancer that involves regular PSA tests and check-ups. Watchful waiting can be suitable for older men where the cancer is not likely to cause a problem in their lifetime.
Surgery with curative intent removes the whole prostate (radical prostatectomy). The main side effects may include impotence and incontinence.
Radiation therapy (radiotherapy)
Radiation therapy (radiotherapy) is one treatment offered to men with early prostate cancer. It may also be offered if surgery is not an option.
Radiation therapy can be given either with external beam radiation therapy (EBRT) or by implanting radioactive seeds (brachytherapy). Side effects are similar to surgery, however bowel problems may also occur.
Androgen deprivation therapy (hormone therapy)
Some cancers need certain hormones to grow. Prostate cancer needs testosterone. Androgen deprivation therapy or ADT (once called hormone therapy) is used to slow the production of testosterone. ADT is often used before, during and after radiation therapy and is sometimes given with chemotherapy.
ADT can be given with injections or in tablet form. Although no longer commonly used, surgery to remove part or all of the testicles may be preferable in some cases.
In some cases of prostate cancer, your medical team may talk to you about palliative care. Palliative care aims to improve your quality of life by alleviating symptoms of cancer.
As well as slowing the spread of prostate cancer, palliative treatment can relieve pain and help manage other symptoms. Treatment may include radiation therapy, chemotherapy or other drug therapies.
Treatment TeamDepending on your treatment, your treatment team may consist of a number of different health professionals, such as:
- GP (General Practitioner)- looks after your general health and works with your specialiststo coordinate treatment.
- Urologist- specialises in the treatment of diseases of the urinary system (male and female) and the male reproductive system.
- Radiation oncologist- prescribes and coordinates radiation therapy treatment.
- Radiologist- interprets diagnostic scans (including CT, MRI and PET scans).
- Medical oncologist- prescribes and coordinates the course of chemotherapy.
- Cancer care coordinators- coordinate your care, liaise with the multidisciplinary team and support you and your family throughout treatment.
- Cancer nurses- assist with treatment and provide information and support throughout your treatment.
- Continence care nurse/urology care coordinator- supports people with bladder and bowel management before and after cancer treatment.
- Sexual therapist- qualified counsellor who has been trained to help patients manage sexual concerns.
- Other allied health professionals- such as social workers, pharmacists and counsellors.
Screening for prostate cancer
There are no tests available with sufficient accuracy to screen populations of men for early signs of prostate cancer. However, early detection and treatment can significantly improve prostate cancer survival.
The test most commonly used to aid early detection of prostate cancer is the prostate specific antigen (PSA) blood test. This is not a diagnostic test as it can only indicate changes in the prostate. If you are concerned about prostate cancer you should talk to your doctor and make an informed choice about whether to have one of the tests designed to find early signs of prostate cancer, in view of the potential risks and benefits.
For more information see our page on early detection of prostate cancer.
Preventing prostate cancer
There are no proven measures to prevent prostate cancer.
Prognosis for prostate cancer
It is not possible for a doctor to predict the exact course of a disease, as it will depend on each person's individual circumstances. However, your doctor may give you a prognosis, the likely outcome of the disease, based on the type of prostate cancer you have, the test results, the rate of tumour growth, as well as your age, fitness and medical history.
Prostate cancer often grows slowly and even more aggressive types tend to grow more slowly than other types of cancer. If diagnosed early, prostate cancer has one of the highest five year survival rates.
Understanding Prostate Cancer, Cancer Council Australia © 2020. Last medical review of source booklet: March 2020.
Australian Institute of Health and Welfare (AIHW). Australian Cancer Incidence and Mortality (ACIM) books: Prostate cancer. Canberra: AIHW.